Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) Current ratio

Alert me on Current ratio

Regeneron Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 3.3×, down 0.8× from fiscal 2025 (4.1×). Over the past ten years it has ranged from 2.6× (fiscal 2016) to 5.7× (fiscal 2023); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 4.7× and above the Healthcare sector median of 3.0×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 4.1× (12.80%)
FY2024 4.7× (16.85%)
FY2023 5.7× 12.53%
FY2022 5.1× 41.88%
FY2021 3.6× (1.70%)
FY2020 3.6× (1.15%)
FY2019 3.7× (17.93%)
FY2018 4.5× 17.05%
FY2017 3.8× 49.04%
FY2016 2.6× (28.72%)

Quarterly newest first

Period Current ratio Change
Jun 2026 3.3× (6.44%)
Mar 2026 3.6× (13.59%)
Dec 2025 4.1× 1.53%
Sep 2025 4.1× (11.62%)
42 more quarters

Against its own ten years

Low 2.6× High 5.7×
Ten-year median 3.8×
Current reading's percentile 64

Current ratio against peers

Company Current ratio
ROIV Roivant Sciences Ltd. compare 16.7×
RVMD Revolution Medicines, Inc. compare 11.4×
ARGX argenex SE compare 5.1×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 3.4×
REGN Regeneron Pharmaceuticals, Inc. 3.3×
VRTX Vertex Pharmaceuticals Incorporated compare 3.2×
ALNY Alnylam Pharmaceuticals, Inc. compare 3.1×
RPRX Royalty Pharma PLC compare 2.8×
MRNA Moderna, Inc. compare 2.3×
Biotechnology industry median 4.7×
Healthcare sector median 3.0×
Market median 1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on REGN